Bio-Thera Solutions announced that its phase III study of BAT2206 demonstrated it is highly similar to Janssen’s Stelara® (ustekinumab) in patients with moderate to severe plaque psoriasis. Bio-Thera confirmed it will present the results at a future medical meeting or in a publication.
On 16 June 2023, Bio-Thera entered a distribution agreement for BAT2206 in Brazil. In 2021 Bio-Thera entered into a licence agreement with Hikma for the US (with option to add Europe) and with Pharmapark for Russia and other CIS countries.